A breakthrough in diabetes treatment has arrived as the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Teplizumab, the first medicine that can slow down the progression of type 1 diabetes.
Experts are calling the approval a “game changer” because the drug can delay the worsening of the disease and reduce the need for lifelong daily insulin injections. Until now, insulin has been the only treatment available for people with type 1 diabetes, a chronic condition affecting around 400,000 people in the UK.
Type 1 diabetes occurs when the body’s immune system destroys insulin-producing cells in the pancreas, leaving patients unable to naturally regulate blood sugar. Unlike type 2 diabetes, where insulin production is reduced or less effective, type 1 almost completely stops the body from producing insulin.
The newly approved drug, marketed as Tzield, offers hope to patients by slowing down this process and improving their quality of life. Health experts say this marks the beginning of a new chapter in the fight against diabetes.
Ahmed Musa, General Manager of Sanofi UK and Ireland, said: “A century ago, the discovery of insulin revolutionized diabetes treatment. Today’s approval is the next big step forward.”
Doctors believe the medicine will not only change how type 1 diabetes is treated but could also lead to further medical advances that transform care for millions of patients worldwide.
